FDA approves blood cancer therapeutic from AbbVie and Genmab
AbbVie and Genmab recently received approval from the US FDA for their joint venture, the blood cancer therapy epcoritamab, sold under the brand name EPKINLY.
Epcoritamab is the first therapy of the sort to be approved by the FDA for relapsed or refractory large B-cell lymphoma, under their accelerated approval programme. The treatment is the only T-cell engaging bispecific antibody currently on the market.
The therapy is used to treat an advanced form of large B-cell lymphoma, a cancer that starts in the lymphatic system affecting B cells, with new cases occuring in 150,000 people worldwide. The patients receiving this therapy must have received at least two previous forms of treatment to be eligible.
"DLBCL is an aggressive cancer type that can rapidly progress and resist treatment. The FDA approval of EPKINLY represents a new treatment mechanism of action for third line DLBCL patients. As a non-chemotherapy, single-agent treatment for DLBCL patients, we hope that EPKINLY can effectively treat this aggressive cancer type and can be used for patient care quickly and in an off the shelf form for physicians," stated Thomas Hudson, Senior Vice President of R&D and Chief Scientific Officer at AbbVie.
"The approval is just the first step, with our partner Genmab, towards a shared goal of developing a core therapy for patients with B-cell malignancies."
Epcoritamab showed a positive and durable response upon testing, leading to the approval. Approvement further than the accelerated approval will hinge on the results from confirmatory clinical trials. The treatment is currently undergoing Phase III randomised controlled trials to test its use as a mono- or combination therapy in a range of blood cancers.
AbbVie is working on an expanded oncology portfolio with Genmab, leading to this focus on blood cancers with a view to advance the treatment pipeline. Epcoritamab is the third approval for a blood cancer treatment from AbbVie.
"Patients with DLBCL who relapse or are refractory to currently available therapies have limited options. Generally, the prognosis for these patients is poor and management of this aggressive disease can be challenging," explained Tycel Phillips, Associate Professor, Department of Hematology & Hematopoietic Cell Transplantation at City of Hope Medical Centre.
"Epcoritamab is a subcutaneous bispecific antibody that offers an additional treatment option for this patient population. With this approval, patients who are in need of additional therapy may have the opportunity to receive epcoritamab after failure to respond or relapse after two or more systemic therapies."
Source: AbbVie News Center. EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [Date accessed 22/05/2023].
Related News
-
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Women in Pharma: Marketing for the other half in healthcare
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. This instalment highlights not only the importance of ma... -
News CAR-T therapy for renal cell carcinoma gains fast track approval
Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company. -
News CPHI Podcast Series: The ripple effects of nearshoring in pharma
In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subs... -
News Bringing the pharmaceutical supply chain closer to home
The pharmaceutical supply chain has encountered numerous disruptions in the last few years, impacting procurement, manufacturing, packaging, and distribution operations within the pharmaceutical industry. Read about the rise in calls for near/resh... -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News President Biden's executive order to increase access to contraception
In the USA, President Joe Biden will be signing an executive order to expand access to contraception.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance